On January 21, 2026, Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (NASDAQ: KPTI), completed the sale of 265 shares of the company’s common stock at $5.96 per share, yielding proceeds of approximately $1,579. This disposition is part of an automatic sale program established on May 27, 2021, designed to satisfy withholding tax obligations arising from the vesting of restricted stock units.
Post transaction, Abate retains direct ownership of 22,580 shares in Karyopharm Therapeutics, maintaining significant insider equity.
In tandem with this insider activity, Karyopharm announced preliminary unaudited total revenue for the full year 2025 of around $145 million. A substantial portion of this revenue was generated domestically, with the U.S. net product sales of Karyopharm’s oncology medication XPOVIO (selinexor) reaching roughly $115 million over the year. The fourth quarter alone contributed approximately $32 million in sales from the drug.
Additionally, the company reported a sequential quarterly revenue growth of 13.4% for the third quarter of 2025, totaling $44 million, despite recording a net loss of $33.1 million for the period.
Market analysts remain favorable on Karyopharm’s outlook ahead of pivotal clinical milestones. Piper Sandler has reaffirmed its Overweight rating and a $12.00 price target, spotlighting Karyopharm as a top investment pick for 2026 in anticipation of Phase III trial data for selinexor combined with JAKIFI in myelofibrosis expected in March 2026.
Similarly, RBC Capital sustains an Outperform rating with a $19.00 price objective, emphasizing optimism toward selinexor’s application in frontline treatment of myelofibrosis. Expert opinion leaders have conveyed confidence in managing potential side effects like nausea through effective anti-emetic protocols and patient education.
This insider transaction and financial update illustrate ongoing confidence by company leadership and analysts in Karyopharm’s growth trajectory amid advancing clinical programs.